Interleukin-33: a novel mediator with a role in distinct disease pathologies
Article first published online: 16 DEC 2010
© 2010 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 269, Issue 1, pages 29–35, January 2011
How to Cite
Kurowska-Stolarska, M., Hueber, A., Stolarski, B. and McInnes, I. B. (2011), Interleukin-33: a novel mediator with a role in distinct disease pathologies. Journal of Internal Medicine, 269: 29–35. doi: 10.1111/j.1365-2796.2010.02316.x
- Issue published online: 16 DEC 2010
- Article first published online: 16 DEC 2010
- Accepted manuscript online: 10 NOV 2010 11:52AM EST
Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB (Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK). IL-33 – a novel mediator with a role in distinct disease pathologies (Key Symposium). J Intern Med 2011; 269: 29–35.
Abstract. Interleukin-33 (IL-33) is a novel member of IL-1 cytokine family. It can act both as a nuclear factor and as a soluble mediator; however, the precise role of IL-33 within the nucleus is still not clear. As a cytokine, IL-33 is suggested to function as an alarmin that is released upon endothelial or epithelial cell damage. As such, IL-33 targets multiple cell types thereby alerting the immune system to endogenous trauma such as physical stress or infection. However, a dysregulated release of IL-33 has a potential to drive distinct pathologies. In this review, we discuss the contribution of IL-33 to the pathophysiology of asthma, arthritis, obesity and atherosclerosis as well as the potential of IL-33 for therapeutic intervention.